Imatinib Alters Agonists-mediated Cytoskeletal Biomechanics in Lung Endothelium
AffiliationUniv Arizona, Dept Med
MetadataShow full item record
PublisherNATURE PUBLISHING GROUP
CitationImatinib Alters Agonists-mediated Cytoskeletal Biomechanics in Lung Endothelium 2017, 7 (1) Scientific Reports
Rights© The Author(s) 2017. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractThe endothelium serves as a size-selective barrier and tightly controls the fluid exchange from the circulation to the surrounding tissues. In this study, a multiplexed microscopy characterization is developed to study the spatio-temporal effects of Abl kinases on endothelial cytoskeletal structure using AFM, SEM, and immunofluorescence. Sphingosine 1-phosphate (S1P) produces significant endothelial barrier enhancement by means of peripheral actin rearrangement. However, Abl kinase inhibition by imatinib reduces rapid redistribution of the important cytoskeletal proteins to the periphery and their association with the cortical actin ring. Herein, it moderates the thickness of the cortical actin ring, and diminishes the increase in elastic modulus at the periphery and cytoplasm. These findings demonstrate that imatinib attenuates multiple cytoskeletal changes associated with S1P-mediated endothelial barrier enhancement and suggest a novel role for Abl kinases in mediating these S1P effects. These observations bridge the gap between molecule dynamics, structure complexity and function connectivity across varied length-scales to improve our understanding on human pulmonary endothelial barrier regulation. Moreover, our study suggests a framework for understanding form-function relationships in other biomechanical subsystems, wherein complex hierarchical organization programmed from the molecular scale to the cellular and tissue levels has an intimate relationship to the overall physiological function.
VersionFinal published version
SponsorsSoft and Hybrid Nanotechnology Experimental (SHyNE) Resource [NSF NNCI-1542205]; MRSEC program at the Materials Research Center [NSF DMR-1121262]; International Institute for Nanotechnology (IIN); Keck Foundation; State of Illinois, through the IIN; National Science Foundation ; National Heart Lung Blood Institute NIH grant [P01 HL 58064, R56 HL HL56088144-06A1]; National Natural Science Foundation of China 
- The Significant Role of c-Abl Kinase in Barrier Altering Agonists-mediated Cytoskeletal Biomechanics.
- Authors: Wang X, Wang L, Garcia JGN, Dudek SM, Shekhawat GS, Dravid VP
- Issue date: 2018 Jan 17
- Differential involvement of ezrin/radixin/moesin proteins in sphingosine 1-phosphate-induced human pulmonary endothelial cell barrier enhancement.
- Authors: Adyshev DM, Moldobaeva NK, Elangovan VR, Garcia JG, Dudek SM
- Issue date: 2011 Dec
- Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain kinase to regulate endothelial barrier function.
- Authors: Dudek SM, Chiang ET, Camp SM, Guo Y, Zhao J, Brown ME, Singleton PA, Wang L, Desai A, Arce FT, Lal R, Van Eyk JE, Imam SZ, Garcia JG
- Issue date: 2010 Nov 15
- Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase.
- Authors: Dudek SM, Jacobson JR, Chiang ET, Birukov KG, Wang P, Zhan X, Garcia JG
- Issue date: 2004 Jun 4
- S1P induces FA remodeling in human pulmonary endothelial cells: role of Rac, GIT1, FAK, and paxillin.
- Authors: Shikata Y, Birukov KG, Garcia JG
- Issue date: 2003 Mar